## COO: The Cooper Companies, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.4% below STRENGTH zone (3.0-6.0%); PEG 2.14 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($79.02)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Hologic Trading Near 52-Week High: How Should You Play the Stock?**
- Source: Finviz | 20260105T135404 | Neutral | Relevance: 66%
- Hologic's shares closed near their 52-week high, outperforming its industry and sector, driven by strong growth in Molecular Diagnostics, Breast Health, and GYN Surgical divisions, alongside a proposed $18.3 billion take-private deal. Despite macroeconomic headwinds and tariffs, the company's innovation, clinical evidence, and regulatory approvals suggest a "hold" position for current investors due to its favorable price performance and appealing valuation. Prospective buyers are advised to wait for more clarity.

**2. VIRGINIA RETIREMENT SYSTEMS ET Al Boosts Stock Holdings in WisdomTree, Inc. $WT**
- Source: MarketBeat | 20260103T110930 | Neutral | Relevance: 65%
- VIRGINIA RETIREMENT SYSTEMS ET Al significantly increased its stake in WisdomTree, Inc. (NYSE:WT) by 311.4% in Q3, now owning 133,700 shares valued at approximately $1.86 million. Institutional investors now hold about 78.6% of WisdomTree, which reported beating Q3 earnings estimates with $0.23 EPS and $125.6 million in revenue, an 11% year-over-year increase. The company also pays a quarterly dividend of $0.03 (1.0% yield) and has a consensus analyst price target of $14.08.

**3. United Therapeutics Corporation $UTHR Shares Bought by Merit Financial Group LLC**
- Source: MarketBeat | 20260103T110920 | Neutral | Relevance: 62%
- Merit Financial Group LLC has significantly increased its stake in United Therapeutics Corporation (UTHR), boosting its holdings by 56.3% in the third quarter to 7,416 shares valued at approximately $3.11 million. This comes as United Therapeutics reported strong Q3 earnings, beating EPS estimates, and analysts maintain a "Moderate Buy" rating with an average target price of $505. However, the company has also seen substantial insider selling recently, with insiders disposing of over 618,000 shares worth around $288 million in the past 90 days.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Citigroup | $88 | $72 | +22% |
| 2025-12-08 | Morgan Stanley | $83 | $76 | +9% |
| 2025-12-08 | Goldman Sachs | $71 | $64 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Citigroup | main | Neutral |
| 2025-12-08 | Morgan Stanley | main | Equal-Weight |
| 2025-12-08 | Goldman Sachs | main | Sell |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 10 ($1.30M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.2% (-1.1%)
- Blackrock Inc.: 7.8% (-0.8%)
- Capital World Invest: 5.4% (+25.7%)
- T. Rowe Price Invest: 5.0% (+33.2%)
- State Street Corpora: 4.4% (-0.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 3 raises (avg +14%) could attract flows.
- Momentum building: MRS_10 improving +1.5% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 2.14 elevated, pricing in significant growth expectations. Analyst sentiment positive (3 raises, avg +14%). Insider buying signal ($1.3M), management confidence. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $16.4B |
| Beta | 1.03 |
| 52W Range | $61.78 - $100.24 |
| Short Interest | 3.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.14 |
| Forward P/E | 16.7 |
| Current P/E | 18.4 |
| YoY Growth | 9.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -1.1% to 0.4% (+1.5% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.6pp (needs >3.0% for momentum thesis). MRS_5 at 0.6% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.41% (CS: 45) | Neutral |
| RSI_14 | 61.3 | Neutral |
| MACD Histogram | -0.37 | Bearish |
| vs SMA20 | 1.012x | Above |
| vs SMA50 | 1.082x | Above |
| vs SMA200 | 1.111x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $82.74
- **Stop Loss:** $79.02 (4.5% risk)
- **Target:** $86.46 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 231
- **Position Value:** $19,112.94
- **Portfolio %:** 19.11%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-03-05 (Est: $1.03)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.11 | $1.15 | +3.3% |
| 2025Q3 | $1.07 | $1.10 | +3.0% |
| 2025Q2 | $0.93 | $0.96 | +3.3% |
| 2025Q1 | $0.91 | $0.92 | +0.9% |

---
*RULE-based L3 | 2026-01-07 09:35 | MRS_10*